- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.09. | RedChip Companies, Inc.: Anixa Biosciences and Nexalin Technology Interviews to Air Nationally on the RedChip Small Stocks, Big Money Show on CNBC and Bloomberg TV | 512 | ACCESS Newswire | ORLANDO, FL / ACCESS Newswire / September 11, 2026 / RedChip Companies will air interviews with Anixa Biosciences Inc. (NASDAQ:ANIX) and Nexalin Technology Inc. (NASDAQ:NXL) on the RedChip Small Stocks... ► Artikel lesen | |
| 03.09. | Nexalin Technology, Inc.: Nexalin Technology Announces New Secondary Analysis of Previously Published Clinical Trial Data Reveals Previously Unreported Improvements in Memory, Comprehension and Language Function in Alzheimer's Patients; ADAS-Cog ... | 3 | GlobeNewswire (USA) | ||
| 27.08. | Nexalin Technology beschließt Reverse-Aktiensplit im Verhältnis 1:30 | 3 | Investing.com Deutsch | ||
| 27.08. | Nexalin Technology approves 1-for-30 reverse stock split | 3 | Investing.com | ||
| 27.08. | Nexalin Technology announces 1-for-30 reverse stock split | 2 | Seeking Alpha | ||
| 27.08. | Nexalin Technology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.08. | Nexalin Technology, Inc.: Nexalin Technology Announces Reverse Stock Split | 421 | GlobeNewswire (Europe) | HOUSTON, TX, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the "Company" or "Nexalin"), announces that its board of directors has approved a 1-for-30 reverse stock split... ► Artikel lesen | |
| NEXALIN TECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 17.08. | Nexalin Technology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.08. | Nexalin Technology, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 27.07. | Nexalin Technology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 23.06. | Nexalin Technology, Inc.: Nexalin Technology Announces that the Investigator of Its Brazilian Clinical Trial Received the Young Researcher Award at BRAIN 2026 for Research Evaluating the Company's Proprietary DIFS Platform | 1 | GlobeNewswire (USA) | ||
| 17.06. | Nexalin Technology, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 10.06. | Nexalin Technology, Inc.: Nexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Quality of Life ... | 281 | GlobeNewswire (Europe) | Study using Nexalin's proprietary DIFS 15 mA 77.5 Hz treatment platform demonstrated rapid, large-magnitude improvements in anxiety and depression with benefits maintained at 8-week follow-up Results... ► Artikel lesen | |
| 10.06. | EXCLUSIVE: Nexalin Brazil Trial Shows Benefits Across Anxiety, Sleep And Quality Of Life | 2 | Benzinga.com | ||
| 04.06. | Nexalin receives U.S. patent for neurostimulation method | 1 | Investing.com | ||
| 04.06. | Nexalin erhält US-Patent für Neurostimulationsverfahren gegen Angst, Depression und Schlaflosigkeit | 1 | Investing.com Deutsch | ||
| 04.06. | Nexalin Technology, Inc.: Nexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and Insomnia | 255 | GlobeNewswire (Europe) | Newly issued U.S. patent expected to provide core intellectual property protection through 2042, further strengthening Nexalin's proprietary position in non-invasive frequency-based deep-brain neurostimulation... ► Artikel lesen | |
| 27.05. | Nexalin Technology: EPS übertrifft Schätzungen - Umsatz schlechter als erwartet | 1 | Investing.com Deutsch | ||
| 21.05. | Nexalin: $1.3 Million PONM Acquisition Expands AI-Integrated Neurostimulation Platform Ahead Of FDA Trial | 1 | pulse2.com | ||
| 21.05. | Nexalin Technology, Inc.: Nexalin Technology Secures Key Neurostimulation Legislative Provision & Commends U.S. House-Passed Report Language Expanding Non-Invasive Deep Brain Neurostimulation Research at the Department of Veterans Affairs for ... | 3 | GlobeNewswire (USA) |
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TELADOC HEALTH | 5,460 | -0,36 % | Teladoc Health, Inc.: Teladoc Health Appoints Financial Executive Mark Anquillare to Its Board of Directors | NEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in virtual care, today announced the appointment of Mark V. Anquillare to its board of directors. Mr. Anquillare... ► Artikel lesen | |
| SERNOVA BIOTHERAPEUTICS | 0,068 | +5,26 % | Sernova Biotherapeutics Inc: Sernova shareholder Sangha to vote "yes" in takeover | ||
| CERENOME | 1,744 | -0,57 % | Cerenome, Inc.: Cerenome Appoints Samantha Fowlkes as Vice President and Head of Commercial Sales, CNSide Diagnostics Division | HOUSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), today announces the appointment of Samantha... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 2,060 | +5,10 % | ATOSSA THERAPEUTICS, INC. - 8-K, Current Report | ||
| SONOMA PHARMACEUTICALS | 2,350 | -100,00 % | Sonoma Pharmaceuticals: Historischer Wendepunkt - darum fliegt die Aktie! | Volltreffer: Bereits im Frühjahr hatte ich die positive Entwicklung bei Sonoma Pharmaceuticals antizipiert und die Nano-Cap-Aktie als hochinteressante Turnaround-Spekulation vorgestellt. Damals hatte... ► Artikel lesen | |
| TANDEM DIABETES | 14,900 | +1,36 % | Tandem Diabetes Care, Inc.: Tandem Diabetes Care Launches t:slim X2 Insulin Pump Compatibility with Abbott FreeStyle Libre 3 Plus Sensor in Five International Markets | Compatibility now available in five countries, with additional markets expected throughout 2026.Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company... ► Artikel lesen | |
| CO-DIAGNOSTICS | 0,970 | +2,57 % | Co-Diagnostics, Inc. - 8-K, Current Report | ||
| QUIDELORTHO | 9,076 | -1,99 % | QuidelOrtho Corporation: QuidelOrtho Reports Second Quarter 2026 Financial Results | ? Total revenue grew 3% reported and 2% constant currency, primarily driven by Labs and Point of Care growth ?
? Excluding China, total revenue grew 6% both as... ► Artikel lesen | |
| VERU | 2,395 | -0,62 % | Veru Inc.: Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress | -- Phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight loss is fully enrolled with 239 patients - -- Phase 2b PLATEAU clinical trial interim analysis and... ► Artikel lesen | |
| LIFEWARD | 7,030 | -1,82 % | Lifeward legt Termin für jährliche und außerordentliche Hauptversammlung 2026 fest | ||
| CLOVER HEALTH INVESTMENTS | 3,920 | +1,03 % | Clover Health Investments, Corp.: Clover Health Announces Departure of Chief Financial Officer and Appointment of Interim Chief Financial Officer; Reiterates Most Recently Issued Financial Guidance for Full Fiscal Year 2026 | WILMINGTON, Del., April 01, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) ("Clover" or the "Company"), a physician enablement company committed to bringing access to great... ► Artikel lesen | |
| SENSEONICS | 7,850 | -5,99 % | Senseonics sees activist investor take a major stake | ||
| TEMPEST THERAPEUTICS | 0,965 | -0,35 % | Tempest Therapeutics: Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform | -Transaction complements Tempest's existing CD7-targeted lipid nanoparticle in vivo CAR-T delivery platform, which is planned to enter the clinic later this year -Lead BCMA/GPRC5D dual-targeting in... ► Artikel lesen | |
| NANO-X IMAGING | 0,745 | +1,54 % | Nano-X Imaging Ltd. - 6-K, Report of foreign issuer | ||
| IMUNON | 1,220 | 0,00 % | Imunon, Inc.: IMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer | Enrollment momentum exceeding expectations is based on highly promising survival (OS) data and well tolerated safety profile demonstrated in the Company's large, randomized Phase II study, OVATION... ► Artikel lesen |
Das Unternehmen NEXALIN TECHNOLOGY INC kann der Branche Gesundheitswesen zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 4,870 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEXALIN TECHNOLOGY INC finden Sie auf Wallstreet Online.